MedTrace Logo

Unlocking Dystonia From Parkinson's Disease With Directional DBS Technology

NCT03409120 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2022-11-10

Study results available
· View outcomes & findings →

Summary

This study occurs during five visits that are already scheduled as part of "Biomarkers to Guide Directional DBS for Parkinson's Disease" (ClinicalTrials.gov Identifier: NCT03353688). If participants have dystonia associated with Parkinson's disease, the investigators will consent and administer one additional rating scale (Burke-Fahn-Marsden Dystonia Rating Scale) to assess the severity of dystonia.

Conditions

  • Dystonia-Parkinsonism, Adult-Onset
  • Parkinson Disease

Interventions

DEVICE

Boston Scientific Vercise PC IPG with directional DBS lead

We will contrast the effects of omnidirectional versus directional STN DBS on dystonia symptoms in patients with PD.

Sponsors & Collaborators

  • Michael J. Fox Foundation for Parkinson's Research

    collaborator OTHER

  • University of Alabama at Birmingham

    lead OTHER

Principal Investigators

  • Harrison C Walker, MD · Associate Professor of Neurology

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2021-06-30
Completion
2022-06-30
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03409120 on ClinicalTrials.gov